Once validated chemical leads are identified within a project then a much more focused approach is adopted to prepare very close analogues designed to probe important structural features of the molecule. Smaller numbers of compounds are prepared which ask specific questions about the interactions between the biological target and the molecule of interest.
The objective of this type of work is to optimise the properties to allow the further testing of compounds in advanced disease models. Computational input into LO is often desirable.
"The Sygnature team has proven itself in the crucible of some very challenging chemistry, bringing both creativity and diligence to bear on our projects. Molecules provided by Sygnature have validated our breakthrough predictive drug engineering capabilities.”
John Griffin, CSO of Pharmix Corp.